The plasma GFAP level was greater in the Alzheimer’s disease group (229.46 ± 114.47 pg/mL) than in the CU group (87.92 ± 44.84 pg/mL, P < 0.001) and the other two patient groups (SIVD, 160.14 ± 100.94 pg/mL, P < 0.01; FTLD, 101.52 ± 82.53 pg/mL, P < 0.001) and was greater in the SIVD group than in the CU group (P < 0.001) but did not significantly differ between the FTLD and CU groups (P > 0.05). This evidence concerns the gene GFAP and Alzheimer disease.